Densitas and ScreenPoint Medical aim to improve patient outcomes

Halifax, NSAnd June 7, 2023 /CNW/ – Densitas Inc. , a global provider of artificial intelligence solutions for digital mammography and breast cancer screening, today announced a strategic partnership with ScreenPoint Medical, a developer of innovative breast imaging solutions. The two companies will work together to scale their cutting-edge AI solutions, transforming the delivery of care for mammography providers and patients.

High-quality imaging is essential for accurate detection of breast cancer. However, up to 50% of mammograms fail to meet image quality criteria, and in 80% of cases the problem is poor positioning. Through this strategic partnership, Densitas and ScreenPoint will bring their cutting-edge AI solutions to address these critical concerns of poor image quality and positioning, with the goal of improving breast cancer detection accuracy and achieving better patient outcomes.

MoAbdolell, CEO of Densitas, said that we must rely on practical and scalable solutions that build on precision technologies in order to improve the quality of mammography and breast cancer diagnoses, both in terms of the health of individuals and the health of populations. We are pleased to partner with ScreenPoint in our shared vision of applying accurate breast imaging procedures to every mammogram taken in all screening exams to support patients through the screening, diagnosis, treatment and prevention of breast cancer.

Densitas intelliMammot™ is an advanced mammography quality improvement platform that supports clinical care teams to improve image quality, operational efficiencies, compliance with EQUIP guidelines for FDA and American College of Cardiology mammography quality standards, and clinical trust backed by best-in-class AI solutions.

ScreenPoint’s Transpara software uses deep learning to analyze mammograms to ensure the accuracy of early detection tests for breast cancer. Transpra has been shown to reduce mammogram reading time for radiologists, helping to improve accuracy and productivity in a medical specialty facing extraordinary levels of burnout.

Early detection of breast cancer is key to supporting effective treatment, said Mark Koeniger, CEO of ScreenPoint Medical. We are pleased to partner with Densitas, a company that shares our view of the importance of high-quality mammography to improve awareness and access to our solutions, leading to continuous quality improvement throughout breast cancer screening.

Together, the two best-in-class AI solutions can help improve the accuracy of breast cancer screening, avoid unnecessary procedures resulting from false-positive results, detect cancer earlier, and reduce costly tech recalls. This information helps radiologists interpret results and enables them to make informed decisions regarding follow-up examination or diagnostic procedures.

About Densitas

densities ^{is a global leader in AI solutions for breast cancer screening, with a focus on quality, safety, efficiency and accuracy technologies. Densitas intelliMammotm helps hospitals and imaging centers that offer mammography services achieve efficiency, meet FDA and ACR compliance requirements, and support early detection and treatment of breast cancer. To find out more, visit www.densitashealth.com.}

About ScreenPoint

ScreenPoint Medical transforms research using cutting-edge machine learning techniques into accessible technology for radiologists to improve screening workflows, decision confidence, and breast cancer risk assessment. The Transpara solution is trusted by radiologists around the world as it was developed by specialists in machine learning and image analysis and enhanced with feedback from renowned mammography professionals around the world.

SOURCE Densitas Inc.

The statement has been sent Jun 7, 2023 9:30 AM and distribution: